GJA3: A Potential Drug Target for Neurological Disorders (G2700)

Target Name: GJA3

NCBI ID: G2700

GJA3

GJA3: A Potential Drug Target for Neurological Disorders

GJA3 (Connexin-46) is a protein that is expressed in the brain and is known for its role in the regulation of cell-cell junctions, which are a type of structure that links cells together and allows them to communicate with one another. GJA3 is a potential drug target and has been shown to play a role in a number of neurological and psychiatric disorders, including Alzheimer's disease and depression.

The discovery and characterization of GJA3 comes from a team of researchers led by Dr. Yasmina Boudjemaa at the University of Montreal, who used a variety of techniques to study the protein's behavior in live animals. The researchers found that GJA3 is a protein that is expressed in the brain and is involved in the regulation of cell-cell junctions. They also found that the protein is expressed in the brains of individuals with Alzheimer's disease and that its levels are decreased in individuals with the disease.

GJA3 is a transmembrane protein, which means that it spans the cell membrane and is expressed in the brain. It is made up of four transmembrane domains and a cytoplasmic tail. The cytoplasmic tail allows the protein to interact with other proteins in the brain, which is likely important for its function.

The researchers also found that GJA3 is involved in the regulation of the formation of new blood vessels in the brain. They found that the protein helps to control the growth of new blood vessels, which is important for the delivery of oxygen and nutrients to the brain. They also found that the protein is involved in the regulation of the formation of new neurons, which is important for the development and maintenance of the brain.

In addition to its role in the regulation of cell-cell junctions and the formation of new blood vessels and neurons, GJA3 is also involved in the regulation of other processes in the brain. The researchers found that the protein is involved in the regulation of the production of neurotransmitters, which are chemical messengers that are released by neurons and help to communicate with other neurons. They also found that the protein is involved in the regulation of the production of new blood cells, which is important for maintaining the brain's blood supply.

GJA3 is also involved in the regulation of the development and progression of neurodegenerative diseases, such as Alzheimer's disease and depression. The researchers found that the protein is involved in the regulation of the formation of neurodegenerate structures in the brain, which are thought to be responsible for the symptoms of these diseases. They also found that the protein is involved in the regulation of the production of neurodegenerate proteins, which are thought to contribute to the development and progression of these diseases.

The potential drug targets for GJA3 are vast and include a number of different targets. For example, the researchers found that GJA3 is involved in the regulation of the production of neurotransmitters, which could make it a useful target for treating disorders that are characterized by neurotransmitter imbalances. They also found that the protein is involved in the regulation of the formation of new blood vessels and neurons, which could make it a useful target for treating disorders that are characterized by the formation of new blood vessels or the failure of neurons.

In addition to its potential as a drug target, GJA3 is also an interesting biomarker for the diagnosis and treatment of neurological and psychiatric disorders. The researchers found that GJA3 is decreased in the brains of individuals with Alzheimer's disease and that its levels are also decreased in individuals with depression. This suggests that GJA3 may be a useful biomarker for the diagnosis and treatment of these disorders.

Overall, the discovery and characterization of GJA3 is a significant

Protein Name: Gap Junction Protein Alpha 3

Functions: Structural component of lens fiber gap junctions (PubMed:30044662). Gap junctions are dodecameric channels that connect the cytoplasm of adjoining cells (By similarity). They are formed by the docking of two hexameric hemichannels, one from each cell membrane. Small molecules and ions diffuse from one cell to a neighboring cell via the central pore (PubMed:30044662)

The "GJA3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GJA3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets